The mylife Symposium at EASD 2026, Milan

The mylife Diabetes Care Industry Symposium at EASD 2026 “At the Cutting Edge of Automated Insulin Delivery” shared new evidence across pregnancy, the menstrual cycle and fully closed-loop insulin delivery

At the mylife Diabetes Care Industry Symposium at EASD 2026, Professors Helen Murphy, Lia Bally and Roman Hovorka explored how automated insulin delivery (AID) is evolving to address different and changing needs of people living with type 1 diabetes (T1D).

All three speakers combined the current scientific and clinical context with new data presented at EASD 2026, including unpublished and preliminary analyses. Helen Murphy presented new AiDAPT subanalyses extending the evidence for CamAPS FX through pregnancy, labour and postpartum; Lia Bally shared preliminary findings from the MCM-Loop study investigating menstrual-cycle-related changes during myLoop use; and Roman Hovorka presented the first interim real-world analysis comparing CamAPS Liberty with conventional CamAPS FX hybrid closed-loop use.

Pregnancy: from landmark randomized controlled trial (RCT) evidence to national implementation

Professor Helen Murphy opened by highlighting the persistent challenges of T1D in pregnancy. Despite advances in diabetes care and widespread use of continuous glucose monitoring, rates of large-for-gestational-age infants, preterm birth and neonatal care admission remain high. Pregnancy also places particularly demanding requirements on AID, with rapidly changing insulin needs and substantially tighter glucose targets than outside pregnancy.

Against this background, Murphy reviewed the evidence generated by the AiDAPT randomised controlled trial, which she led. AiDAPT demonstrated that CamAPS FX significantly improved maternal glycaemic control compared with standard insulin therapy with CGM, with improvements in pregnancy-specific time in range apparent within the first week. These findings established the clinical evidence for CamAPS FX as a pregnancy-specific HCL system.

Building on the published primary AiDAPT findings, Murphy presented new, previously unpublished subanalyses extending the evidence into clinically important periods around birth and postpartum. Across labour, delivery and inpatient postpartum, women using HCL spent significantly more pregnancy-specific TIR compared to women using standard care. Additional follow-up data provided further insight into glycaemic outcomes during the first six months after delivery.

The presentation then moved from clinical trials to implementation at national scale. Results from the 2025 National Pregnancy in Diabetes Audit demonstrated broad uptake of pregnancy-specific HCL and favourable observed outcomes compared with other HCL approaches, including lower late-pregnancy HbA1c and lower observed rates of preterm birth and large-for-gestational-age infants.

This development is also reflected in national health policy. Pregnancy-specific HCL is recommended and nationally funded in England for women with T1D who are pregnant or planning pregnancy, with ambitious national implementation targets. Murphy's presentation therefore illustrated a continuum from landmark RCT evidence through new clinical analyses to real-world outcomes and implementation within national maternity care.

Menstrual cycle: first systematic insights into cycle-related variability with myLoop

Professor Lia Bally addressed a common but still insufficiently understood challenge for women living with T1D: changing glucose patterns and insulin requirements across the menstrual cycle. She first reviewed the physiological background, including cyclical changes in reproductive hormones and their potential effects on insulin sensitivity, energy expenditure, appetite, behaviour and stress.

Survey findings presented at the beginning of the talk illustrated the clinical relevance of the topic, with both healthcare professionals and women living with diabetes frequently reporting an impact of the menstrual cycle on diabetes management. Bally also highlighted important limitations of previous research, including reliance on bleeding diaries for cycle-phase classification, substantial variability between cycles and limited understanding of how modern adaptive AID responds to these physiological changes.

The MCM-Loop study provides the first systematic clinical investigation of how myLoop powered by CamAPS FX supports glycaemic control across changing insulin requirements during the menstrual cycle. Forty naturally cycling women with T1D were followed over three menstrual cycles while using myLoop. Daily measurements of reproductive hormones and core temperature enabled objective characterisation of cycle phases, complemented by CGM, insulin-delivery, food and activity data.

Bally presented preliminary, previously unpublished findings from 114 ovulatory cycles. TIR remained relatively stable across the analysed phases, despite measurable changes in insulin requirements. From the early follicular to mid-luteal phase, both the total daily insulin and the automated insulin delivery increased. The findings suggest that the adaptive CamAPS FX algorithm responded to changing insulin requirements across cycle phases, helping to maintain a good level of glycaemic control without predefined cycle-specific adjustments.

At the same time, Bally emphasised that population averages do not tell the complete story. More than half of participants reported perceiving cycle-related effects, and variability between women and between individual cycles remains important. The study therefore raises further questions: Which women experience clinically meaningful cycle effects? What determines their magnitude? How closely do objectively measured changes correspond with women's own experience, and could targeted interventions at specific cycle phases provide additional benefit?

CamAPS Liberty: taking automation from hybrid to fully closed loop

Professor Roman Hovorka placed CamAPS Liberty within the continuing evolution of the CamAPS FX platform. While conventional HCL systems automate much of insulin delivery, users still typically need to count carbohydrates, announce meals and deliver meal boluses. These repeated decisions remain an important part of the day-to-day treatment burden of T1D.

CamAPS Liberty takes automation one step further as the first commercially available fully closed-loop (FCL) option for AID users. Rather than being a separate AID system, Liberty is integrated within CamAPS FX as a user-selectable alternative algorithm mode. Users can choose between conventional CamAPS FX HCL operation and Liberty's enhanced FCL algorithm according to their needs and circumstances. With Liberty activated, routine carbohydrate counting and meal or snack boluses are no longer required.

Hovorka reviewed the clinical research programme supporting fully closed-loop insulin delivery before presenting the first interim real-world analysis comparing CamAPS Liberty with conventional CamAPS FX HCL use. The analysis included 597 commercial users with sufficient data before and after activating Liberty, allowing each user to serve as their own comparator.

These preliminary real-world data showed that Liberty met the predefined non-inferiority criteria for all five glycaemic endpoints. Median TIR changed from 70.8% during conventional HCL to 65.8% with Liberty, corresponding to an estimated difference of −4.06 percentage points against the predefined −5 percentage-point non-inferiority margin. At the same time, median daily bolus frequency decreased from 3.9 to 1.5 and bolus insulin decreased substantially.

These first real-world findings provide an important perspective on a central question for FCL therapy: how much of the daily work of diabetes management can be removed while maintaining acceptable glycaemic outcomes? Beta-user feedback complemented the glycaemic data, with 72% of respondents reporting reduced diabetes burden or improved quality of life and 78% indicating that they would recommend Liberty to other CamAPS FX users.

Hovorka also highlighted practical considerations and areas for further optimisation. Adaptation to Liberty may take time, larger or rapidly absorbed meals can remain challenging, and selected users may benefit from targeted interaction with the system. Continued real-world evaluation will help define how FCL can best be personalised to individual needs and preferences.

New evidence across an evolving AID platform

Together, the three presentations highlighted three areas in which the CamAPS platform is extending current AID: pregnancy-specific AID supported by RCT evidence and national real-world implementation; adaptive insulin delivery across the physiological variability of the menstrual cycle; and the transition from hybrid to user-selectable fully closed-loop insulin delivery.

Importantly, the symposium did not only review established evidence. Each speaker presented new or emerging data that advanced the understanding of how CamAPS-based AID can address specific clinical needs and reduce treatment burden. From pregnancy and postpartum, through changing insulin requirements across the menstrual cycle, to the option of reducing routine meal announcement and carbohydrate counting with Liberty, the presentations illustrated the continuing evolution of myLoop powered by CamAPS FX towards adaptive, personalised and increasingly less burdensome diabetes management.

Data status: Several datasets presented at the symposium were preliminary and/or unpublished at the time of EASD 2026 and should be interpreted accordingly. In the recording of the session, the slides with unpublished data are therefore blurred.